Human Leukocyte Antigen (HLA) A*1101-restricted Epstein-Barr virus-specific T-cell receptor gene transfer to target Nasopharyngeal carcinoma
| Autor: | Anthony T.C. Chan, Christine H James, Yong Zheng, Xiaodong Zhuang, Peter F. Searle, Gregory Parsonage, Lee Machado, Asmaa M. Salman, Steven P. Lee, Edwin P. Hui |
|---|---|
| Jazyk: | angličtina |
| Předmět: |
CD4-Positive T-Lymphocytes
Cytotoxicity Immunologic Cancer Research Epstein-Barr Virus Infections Herpesvirus 4 Human Immunology Molecular Sequence Data Receptors Antigen T-Cell Epitopes T-Lymphocyte Gene Expression Human leukocyte antigen Biology CD8-Positive T-Lymphocytes medicine.disease_cause Article Virus Viral Matrix Proteins Interferon-gamma Mice Antigen Transduction Genetic Cell Line Tumor medicine otorhinolaryngologic diseases Animals Humans Nasopharyngeal Carcinoma HLA-A Antigens T-cell receptor Carcinoma Gene Transfer Techniques Nasopharyngeal Neoplasms medicine.disease Epstein–Barr virus Xenograft Model Antitumor Assays HLA-A Tumor Burden Disease Models Animal stomatognathic diseases Nasopharyngeal carcinoma Cancer research Cytokines Female Immunotherapy CD8 |
| ISSN: | 2326-6066 |
| Popis: | Infusing virus-specific T cells is effective treatment for rare Epstein-Barr virus (EBV)–associated posttransplant lymphomas, and more limited success has been reported using this approach to treat a far more common EBV-associated malignancy, nasopharyngeal carcinoma (NPC). However, current approaches using EBV-transformed lymphoblastoid cell lines to reactivate EBV-specific T cells for infusion take 2 to 3 months of in vitro culture and favor outgrowth of T cells targeting viral antigens expressed within EBV+ lymphomas, but not in NPC. Here, we explore T-cell receptor (TCR) gene transfer to rapidly and reliably generate T cells specific for the NPC-associated viral protein LMP2. We cloned a human leukocyte antigen (HLA) A*1101-restricted TCR, which would be widely applicable because 40% of NPC patients carry this HLA allele. Studying both the wild-type and modified forms, we have optimized expression of the TCR and demonstrated high-avidity antigen-specific function (proliferation, cytotoxicity, and cytokine release) in both CD8+ and CD4+ T cells. The engineered T cells also inhibited LMP2+ epithelial tumor growth in a mouse model. Furthermore, transduced T cells from patients with advanced NPC lysed LMP2-expressing NPC cell lines. Using this approach, within a few days large numbers of high-avidity LMP2-specific T cells can be generated reliably to treat NPC, thus providing an ideal clinical setting to test TCR gene transfer without the risk of autoimmunity through targeting self-antigens. Cancer Immunol Res; 3(10); 1138–47. ©2015 AACR. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|